SCM
ANRO icon

SCS Capital Management’s Alto Neuroscience ANRO Stock Holding History

SCS Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$379K Sell
16,840
-16,549
-50% -$307K ﹤0.01% 381
2025
Q4 		$594K Sell
33,389
-33,388
-50% -$420K 0.01% 345
2025
Q3 		$268K Hold
66,777
– – ﹤0.01% 462
2025
Q2 		$147K Hold
66,777
– – ﹤0.01% 536
2025
Q1 		$144K Buy
+66,777
New +$239K ﹤0.01% 498

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCS Capital Management's ANRO Position: Q1 2026 in Review

SCS Capital Management reduced its Alto Neuroscience (ANRO) stake by 50% in Q1 2026, selling an estimated $307K and leaving 16,840 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #381.

SCS Capital Management first reported a position in ANRO in Q1 2025 and has held it in 5 quarters since. The position peaked at $594K in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • SCS Capital Management held 16,840 shares of Alto Neuroscience worth $379K as of Q1 2026.
  • SCS Capital Management sold 16,549 Alto Neuroscience shares in Q1 2026, an estimated $307K.
  • Alto Neuroscience made up ﹤0.01% of SCS Capital Management's portfolio in Q1 2026, its #381 holding.
  • SCS Capital Management first reported a position in Alto Neuroscience in Q1 2025 and has held it in 5 quarters since.
  • SCS Capital Management's Alto Neuroscience position peaked at $594K in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on SCS Capital Management's 13F filing for Q1 2026, filed 11 May 2026.